Chabakshin Research Institute Presents Immune Enhancement System Poster at World Vaccine Conference

Cha Vaccine Institute announced on the 3rd that it will participate in the 'World Vaccine Congress 2023' held in Washington DC, USA, from the 3rd to the 6th (local time), and present a poster on vaccine immune enhancement systems. The World Vaccine Congress is an international conference held annually where vaccine researchers and experts from around the world gather to discuss vaccine development and share research results.

Cha Vaccine Institute CI [Photo by Cha Vaccine Institute]

At this event, Cha Vaccine Institute plans to present a poster titled "Novel TLR2/3 Ligand Based Vaccine Adjuvant Systems for Infectious Diseases and Cancer." Through this, they will introduce their self-developed adjuvants, 'L-pampo' and 'Lipo-pam,' highlighting their superiority over existing adjuvants. They will also present research results demonstrating that these adjuvants show excellent efficacy not only in vaccines for infectious diseases such as hepatitis B, norovirus, and COVID-19-flu but also in cancer vaccines. Additionally, business meetings with global pharmaceutical companies participating in the event are scheduled.

Currently, Cha Vaccine Institute is developing various preventive and therapeutic vaccines for infectious diseases using the adjuvants L-pampo and Lipo-pam. These include the hepatitis B preventive vaccine and chronic hepatitis B therapeutic vaccine 'CVI-HBV-002,' shingles vaccine 'CVI-VZV-001,' cancer vaccine 'CVI-CV-001,' and immuno-oncology agent 'CVI-CT-001.'

Yeom Jeong-seon, CEO of Cha Vaccine Institute, stated, "The immune enhancement technology and vaccine pipeline that Cha Vaccine Institute will showcase are expected to attract significant attention from companies participating in the World Vaccine Congress," adding, "Based on our excellent technological capabilities, we will actively conduct research activities to secure vaccine sovereignty and international competitiveness."